hATTR Amyloidosis, a Diagnosis and Treatment Journey

Olga is a special education teacher from California living with a rare, inherited, rapidly progressive disease called hereditary ATTR amyloidosis, also known as hATTR amyloidosis. Olga will discuss the impact the disease has had on her family’s life, as well as her experience living with it, including her participation in a clinical trial for AMVUTTRA (vutrisiran), a new treatment recently approved by the U.S. FDA to treat the polyneuropathy of hATTR amyloidosis in adults.

Olga is a special education teacher from California living with a rare, inherited, rapidly progressive disease called hereditary ATTR amyloidosis, also known as hATTR amyloidosis. Before Olga was diagnosed, she witnessed how the disease manifested in her mother and twin brother and how their symptoms rapidly progressed. Both suffered from neuropathy and pain in their hands and feet, which ultimately impacted their ability to use their hands or walk. When Olga was eventually diagnosed, she wanted to start treatment early to manage her symptoms and potentially help slow her disease progression. She decided to enroll in the HELIOS-A Phase 3 clinical study of AMVUTTRA (vutrisiran), which was recently approved by the FDA for the treatment of the polyneuropathy of hATTR amyloidosis in adults. Today, Olga is grateful there is an additional treatment option available for patients, including her own relatives.